Edwards lifts 2026 sales growth outlook to 10%-11% while reaffirming $2.95-$3.05 EPS
Seeking Alpha ·
Earnings Call Insights: Edwards Lifesciences (EW) Q2 2026 CEO Bernard Zovighian said the quarter came in ahead of plan: "We delivered stronger-than-expected second quarter sales growth of 12.5%." He tied performance to breadth across therapies and geographies, adding, "our results increasingly reflect
DYAX Investor Sentiment
Bullish (Long) 49% · Bearish (Short) 51%
309 participants
Related News
- Five Point reaffirms approximately $100M 2026 net income as it expects remaining land sales in Q4
- MaxLinear forecasts Q3 revenue of $210M-$220M as it raises 2026 optical data center revenue to $210M-$230M
- Digital Realty forecasts $8.15-$8.20 2026 core FFO per share excluding promote, backed by $4.25B-$4.75B capex plan
- Why Most AI Projects Will Fail — And How to Find the Companies That Won't
- Enova forecasts 30% to 35% adjusted EPS growth in 2026 as Grasshopper deal remains on track for later this year
- SkyWest projects 2026 GAAP EPS in the $11 area while outlining $700M CapEx
